Triplet Therapeutics is a therapeutics company that is developing transformative therapies for the treatment of repeat expansion disorders at their source. The company's mission is to prevent repeat expansion disorders and ensure a future for patients.
Triplet is developing a different treatment for repeat expansion disorders, including Huntington’s disease, spinocerebellar ataxias and myotonic dystrophy and, by addressing the underlying cause of the genetic dysfunction that drives disease onset and progression.
The company comprises of a team with years of expertise in drug discovery, clinical research, genetics, and operations. It is supported by a syndicate of investors who share the company's commitment of transforming the lives of patients and families who are affected by repeat expansion disorders.